聚合酶链反应检测肝病患者血液中纳米细菌的研究

目的 评价PCR检测慢性肝病和肝癌患者血液中纳米细菌(NB)的临床价值.方法 对68例慢性乙型肝炎(CHB)、54例慢性重型乙型肝炎(CSHB)、66例肝硬化(CL)、23例肝癌(HCC)患者采用免疫组化染色、透射电镜扫描和PCR技术,检测血液中的纳米细菌,并与40例健康人结果比较.结果 PCR检测纳米细菌阳性率分别为27.69%、50.00%、61.29%、52.38%和5.00%,慢性肝病和肝癌患者阳性率明显高于健康人(P＜0.005).慢性乙型肝炎阳性率低于其他肝病(P＜0.005).PCR测定结果与免疫组化染色比较,两法阳性率无明显差异(P＞0.05),PCR灵敏度为46.51%,特异性为73.95%,总有效率66.67%.结论 PCR对纳米细菌的检测具有重要的参考价值.慢性肝病和肝癌患者血液中纳米细菌感染率高于健康人.

Detection of Nanobacteria in Blood of Patients with Chronic Hepatopathy by PCR Method

Objective To investigate the infection status of nanobacteria on patients of chronic hepatopathy and hepatocellular carcinoma,and evaluate the clinical value of PCR.Methods In sera of 68 cases of chronic hepatitis B(CHB),56 chronic severe hepatitis B(CSHB),66 cirrhosis of liver(CL)and 23 hepatocellular carcinoma(HCC),nanobacteria were detected by immunohistochemistry stain(IHC),Transmission Electron Microscopy(TEM)and polymerase chain reaction(PCR),compared with 40 healthy people.Results The positive rates of PCR were 27.69%,50.00%,61.29%,52.38% and 5.00% in patients with CHB,CSHB,CL,HCC and normal control respectively(P<0.005).There lies significant difference between CHB and other chronic hepatopathy or hepatocellular carcinoma(P<0.001).The sensitivity,specificity,total efficiency of PCR were 46.51%,73.95% and 66.67% respectively.Conclusions PCR is of great value to identification of nanobacteria.And there is higher infection in the blood of patients with hepatopathy than that of healthy people.